Related Experiment Video
Updated: Sep 21, 2025
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
866
Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
Heather Hampel1, Matthew B Yurgelun2
1Division of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA.
Summary
Germline genetic testing is expanding for cancer patients due to multigene panels and targeted therapies. This article discusses the benefits and risks of offering this testing to all gastrointestinal cancer patients.
Area of Science:
- Oncology
- Genetics
- Medical Ethics
Background:
- Germline genetic testing is increasingly used in cancer care.
- Multigene panels, reduced costs, and FDA-approved targeted therapies drive this trend.
- National Comprehensive Cancer Network guidelines recommend testing for specific cancer types.
Purpose of the Study:
- To debate the advantages and disadvantages of offering germline multigene panel testing to all patients with gastrointestinal (GI) cancer.
- To highlight the benefits, risks, and limitations of this approach.
- To identify research gaps for improving genetic medicine implementation in patient care.
Main Methods:
- Literature review and expert opinion.
- Debate on the pros and cons of universal germline multigene panel testing in GI cancer.
- Analysis of current guidelines and therapeutic advancements.
Main Results:
- Germline multigene panel testing is becoming more accessible and recommended for certain cancers.
- Potential benefits include identifying actionable mutations for targeted therapies.
- Risks and limitations involve interpretation challenges and resource allocation.
Conclusions:
- Universal germline multigene panel testing for all cancer patients, including those with GI cancer, is likely inevitable.
- Further research is needed to address the benefits, risks, and limitations.
- Optimizing genetic medicine implementation is crucial for improving patient outcomes.
